Rofecoxib (Vioxx): a year in review

Stienburg, K. Lynn
April 2001
CMAJ: Canadian Medical Association Journal;4/03/2001, Vol. 164 Issue 7, p1039
Academic Journal
Discusses possible side effects of Rofecoxib, a cyclo-oxygenase (COX)-2 inhibitor used to treat acute and chronic symptoms of osteoarthritis. Five deaths which may have been associated with the drug; Gastrointestinal adverse effects; Cardiovascular reactions; Urinary and metabolic disorders.


Related Articles

  • Lumiracoxib registration cancelled.  // WHO Drug Information;2007, Vol. 21 Issue 4, p291 

    The article reports that the registration of lumiracoxib, an osteoarthritis drug, has been cancelled by the Australia Therapeutic Goods Administration. The use of lumiracoxib, a cyclooxygenase-2 inhibitor, has been found to have serious liver side effects. Lumiracoxib is indicated for...

  • Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect? Weatherall, Mark; Aldington, Sarah; Caldwell, Brent; Beasley, Richard // Journal of the Royal Society of Medicine;Jun2006, Vol. 99 Issue 6, p275 

    The article presents the authors' comments on several inconsistencies in cardiovascular data from the Vioxx Gastrointestinal Outcomes Research (VIGOR) study and the Celecoxib Long-term Arthritis Safety Study (CLASS). They questioned the occurrence of cardiovascular deaths after six months of...

  • EMEA tightens COX-2 restrictions, UK MHRA updates advice.  // Reactions Weekly;2/26/2005, Issue 1040, p2 

    Reports on the move of the European Agency for Evaluation of Medical Products (EMEA) to release safety restrictions for COX-2 inhibitors following an update to the advice published by Great Britain's Medicines and Healthcare products Regulatory Agency in December 2004. Adverse effect of COX-2...

  • Etoricoxib.  // Reactions Weekly;7/2/2011, Issue 1358, p17 

    The article describes the case of a 52-year-old woman who developed fixed drug eruption while receiving oral etoricoxib for back pain, published in the June 2011 issue of the journal "Cutaneous and Ocular Toxicology."

  • Treatment Costs to Prevent or Treat Upper Gastrointestinal Adverse Events Associated with NSAIDs: A Review. Rahme, Elham; Barkun, Alan N.; Adam, Viviane; Bardou, Marc // Drug Safety;2004, Vol. 27 Issue 13, p1019 

    The widespread use of nonselective NSAIDs and cyclo-oxygenase (COX)-2 inhibitors has a substantial impact on healthcare budgets worldwide. The cost of their gastrointestinal (GI) adverse effects is a major component of their direct cost and has received much attention in the literature....

  • Findings from COX 2 studies are released. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);2/19/2005, Vol. 330 Issue 7488, p381 

    Reports on the release of findings from recent studies on COX 2 inhibitors. Results of the study which come just before a FDA hearing into the benefits and risks of the drugs; Findings of the studies;.

  • Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. SWEET, BURGUNDA V.; TOWNSEND, KEVIN A.; TSAI, CHRISTINE Y. // American Journal of Health-System Pharmacy;9/15/2004, Vol. 61 Issue 18, p1917 

    Purpose. The risk of gastrointestinal (GI) toxicity associated with the use of a traditional nonsteroidal antiinflammatory drug (NSAID) versus a cyclooxygenase-2 (COX-2) inhibitor was compared among patients in a managed care organization. Methods. Patients over 18 years old who received a...

  • Lumiracoxib: withdrawal of higher doses.  // WHO Drug Information;2007, Vol. 21 Issue 4, p291 

    The article reports that the supply of 200 mg and 400 mg tablets of lumiracoxib, a cyclooxygenase-2 antiinflammatory medicine, has been withdrawn by Medsafe, the Medicines and Medical Devices Safety Authority of New Zealand. Medsafe decided to withdraw the drug after reviewing local and...

  • Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT).  // PLoS Clinical Trials;Nov2006, Vol. 3 Issue 11, p0001 

    Objectives: The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to evaluate the conventional NSAID naproxen sodium and the selective COX-2 inhibitor celecoxib for primary prevention of Alzheimer's dementia (AD). On 17 December 2004, after the Adenoma Prevention with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics